
SK Biotek Ireland
SK Biotek Ireland
2 Projects, page 1 of 1
assignment_turned_in Project2019 - 2027Partners:ALMAC SCIENCES, GlaxoSmithKline PLC, BASF, Pfizer (Ireland), APC Ltd +34 partnersALMAC SCIENCES,GlaxoSmithKline PLC,BASF,Pfizer (Ireland),APC Ltd,GlaxoSmithKline (United Kingdom),MSD Ireland,Polymateria Ltd,CatScI (United Kingdom),GSK,Pfizer Global R and D,Pfizer (United Kingdom),PEL,Calix (Europe) Limited,Polymateria,SK Biotek Ireland,Dr Reddy's Laboratories UK Ltd,Imperial College London,MSD Ireland,Agilent Technologies (United Kingdom),Astex,Almac Group Ltd,BASF,Eli Lilly (Ireland),SK Biotek Ireland,APC Ltd,SAS UK HQ,Dr. Reddy's Laboratories (United Kingdom),GlaxoSmithKline (Not UK),GlaxoSmithKline (Global),Otsuka (United Kingdom),BASF (Germany),Mettler-Toledo Ltd,Pfizer Global R and D,Eli Lilly S.A. - Irish Branch,Agilent Technologies (United Kingdom),Mettler-Toledo (United States),CatScI Ltd,SAS UKFunder: UK Research and Innovation Project Code: EP/S023232/1Funder Contribution: 6,433,910 GBPChemistry is a key underpinning science for solving many global problems. The ability to make any molecule or material, in any quantity needed in a prescribed timescale, and in a sustainable way, is important for the discovery and supply of new medicines to cure diseases, agrochemicals for better crop yields/protection, as well as new electronic and smart materials to improve our daily lives. Traditionally, synthetic chemistry is performed manually in conventional glassware. This approach is becoming increasingly inadequate to keep pace with the demand for greater accuracy and reproducibility of reactions, needed to support further discovery and development, including scaling up processes for manufacturing. The future of synthetic chemistry will require the wider adoption of automated (or autonomous) reaction platforms to perform reactions, with full capture of reaction conditions and outcomes. The data generated will be valuable for the development of better reactions and better predictive tools that will facilitate faster translation to industrial applications. The chemical and pharmaceutical industry is a significant provider of jobs and creator of wealth for the UK. Data from the Chemical Industries Association (CIA) shows that the chemical industry has a total turnover of £40B, adding £14.4B of value to the UK economy every year, employs 140,000 people directly, and supports a further 0.5M jobs. The sector is highly innovation-intensive: much of its annual spend of £4B on investment in capital and R&D is based on synthetic chemistry with many SME's and CRO's establishing novel markets in Science Parks across the UK regions, particularly in the South East and North West. The demand for graduate recruits by the Chemicals and Pharmaceutical industries for the period 2015-2025 is projected to be between 50,000-77,000, driven by an aging workforce creating significant volumes of replacement jobs, augmented by the need to address skills shortages in key enabling technologies, particularly automation and data skills. This CDT will provide a new generation of molecular scientists that are conversant with the practical skills, associated data science and digital technology to acquire, analyse and utilise large data sets in their daily work. This will be achieved by incorporating cross-disciplinary skills from engineering, as well as computing, statistics, and informatics into chemistry graduate programs, which are largely lacking from existing doctoral training in synthetic chemistry. Capitalising upon significant strategic infrastructural and capital investment on cutting edge technology at Imperial College London made in recent years, this CDT also attracts very significant inputs from industrial partners, as well as Centres of Excellence in the US and Europe, to deliver a unique multi-faceted training programme to improve the skills, employability and productivity of the graduates for future academic and industrial roles.
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=ukri________::5a7b67f0284a79f74c6a88c2f1ac8099&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=ukri________::5a7b67f0284a79f74c6a88c2f1ac8099&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.euassignment_turned_in Project2019 - 2028Partners:Merck KGaA, GlaxoSmithKline PLC, Tocris Bioscience, AstraZeneca plc, Heptares Therapeutics +42 partnersMerck KGaA,GlaxoSmithKline PLC,Tocris Bioscience,AstraZeneca plc,Heptares Therapeutics,University of Bristol,Heptares Therapeutics (United Kingdom),Ziylo,Chemspeed Technologies AG,Astex,SK Biotek Ireland,J-Konsult ltd,Dr. Reddy's Laboratories (United Kingdom),Dr Reddy's Laboratories UK Ltd,Eli Lilly (Ireland),AstraZeneca (United Kingdom),Ziylo,UCB UK,Syngenta Ltd,Merck Sharpe and Dohme Ltd (MSD),Eli Lilly S.A. - Irish Branch,Bayer (Germany),Merck (Germany),GSK (Global),ASTRAZENECA UK LIMITED,UCB Pharma (United Kingdom),UCB Celltech (UCB Pharma S.A.) UK,Chemspeed Technologies AG,Charles River Laboratories (United Kingdom),Concept Life Sciences,J-Konsult ltd,Charles River Laboratories,Syngenta (United Kingdom),Otsuka (United Kingdom),Concept Life Sciences (United Kingdom),Bayer AG,GlaxoSmithKline (United Kingdom),GSK,Eli Lilly (United Kingdom),GSK (Global),Merck (Germany),Merck Sharpe and Dohme Ltd (MSD),Eli Lilly and Company Limited,SK Biotek Ireland,University of Bristol,Tocris Bioscience,Concept Life SciencesFunder: UK Research and Innovation Project Code: EP/S024107/1Funder Contribution: 6,882,770 GBPSynthesis, the science of making molecules, is central to human wellbeing through its ability to produce new molecules for use as medicines and materials. Every new drug, whether an antibiotic or a cancer treatment, is based on a molecular structure designed and built using the techniques of synthesis. Synthesis is a complex activity, in which bonds between atoms are formed in a carefully choreographed way, and training to a doctoral level is needed to produce scientists with this expertise. Our proposed CDT is tailored towards training the highly creative, technologically skilled scientists essential to the pharmaceutical, biotech, agrochemical and materials sectors, and to many related areas of science which depend on novel molecules. Irrespective of the ingenuity of the synthetic chemist, synthesis is often the limiting step in the development of a new product or the advance of new molecular science. This hurdle has been overcome in some areas by automation (e.g. peptides and DNA), but the operational complexity of a typical synthetic route in, say, medicinal chemistry has hampered the wider use of the technology. Recent developments in the fields of automation, machine learning (ML), virtual reality (VR) and artificial intelligence (AI) now make possible a fundamental change in the way molecules are designed and made, and we propose in this CDT to engineer a revolution in the way that newly trained researchers approach synthetic chemistry, creating a new generation of pioneering innovators. Making use of Bristol's extensive array of automated synthetic equipment, flow reactors, peptide synthesisers, and ML Retrosynthesis Tool, students will learn and appreciate this cutting-edge technology-driven program, its potential and its limitations. Bristol has outstanding facilities, equipment and expertise to deliver this training. At its core will be a state-of-the-art research experience in our world-leading research groups, which will form the majority of the 4-year CDT training period. For the 8 months prior to choosing their project, students with complete a unique, multifaceted Technology & Automation Training Experience (TATE). They will gain hands-on experience in advanced techniques in synthesis, automation, modelling and virtual reality. In conjunction with our Dynamic Laboratory Manual (DLM), the students will also expand their experience and confidence with interactive, virtual versions of essential experimental techniques, using simulations, videos, tutorials and quizzes to allow them to learn from mistakes quickly, effectively and safely before entering the lab. In parallel, they will develop their teamworking, leadership and thinking skills through brainstorming and problemsolving sessions, some of them led by our industrial partners. Brainstorming involves the students generating ideas on outline proposals which they then present to the project leaders in a lively and engaging interactive feedback session, which invariably sees new and student-driven ideas emerge. By allowing students to become fully engaged with the projects and staff, brainstorming ensures that students take ownership of a PhD proposal from the start and develop early on a creative and collaborative atmosphere towards problem solving. TATE also provides a formal assessment mechanism, allow the students to make a fully informed choice of PhD project, and engages them in the use of the key innovative techniques of automation, machine learning and virtual reality that they will build on during their projects. We will integrate into our CDT direct interaction and training from entrepreneurs who themselves have taken scientific ideas from the lab into the market. By combining our expertise in synthesis training with new training platforms in automation, ML/AI/VR and entrepreneurship this new CDT will produce graduates better able to navigate the fast-changing chemical landscape.
All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=ukri________::473e3524adf571f4c776d958d3686eef&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eumore_vert All Research productsarrow_drop_down <script type="text/javascript"> <!-- document.write('<div id="oa_widget"></div>'); document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=ukri________::473e3524adf571f4c776d958d3686eef&type=result"></script>'); --> </script>
For further information contact us at helpdesk@openaire.eu